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Relationship between advanced glycoxidation end products, stabile clinical status without signs of acute infection
inflammatory markers/acute-phase reactants, and some auto- have elevated acute phase reactants and inflammatory
antibodies in chronic hemodialysis patients. Uremia and dial- markers in the serum (i.e., CRP, serum amyloid A pro-ysis treatment are associated with uncorrected oxidative and
tein [SAA], and fibrinogen), and this status is describedcarbonyl stress and microinflammation. Elevation of both oxi-
as chronic microinflammation [2, 3]. Moreover, we referdative/carbonyl stress end products (advanced oxidation pro-
tein products (AOPP), advanced glycation end products (AGEs), to a slight, but significant elevation of pregnancy-associ-
and advanced lipoperoxidation end products (ALEs), autoanti- ated plasma protein A (PAPP-A) (25.8  15.5 mU/L in
bodies against modified biological structures, and acute-phase
HD patients as compared with 8.75  2.42 mU/L inreactants (e.g., C-reactive protein [CRP], fibrinogen) seems to
healthy subjects, P 0.05), which could represent a newtake part in the development of various complications, among
them accelerated atherosclerosis. These pathogenic mecha- acute-phase reactant. This protein was first described in
nisms are supposed to act synergically; nevertheless, oxidative pregnant women, where its serum values are extremely
stress shows a closer relationship to inflammation and acute- high [4]. Surprisingly, serum concentrations of PAPP-Aphase reaction than advanced glycation. Its end product,
in HD patients are similar to those presented in patientsAOPP, could, thus, represent a biochemical marker of specific
with acute myocardial infarction [5] (i.e., a threefold eleva-importance.
tion in comparison with healthy men and nonpregnant
women). Inflammatory markers and acute-phase reactants,
Patients on chronic hemodialysis (HD) treatment usu- mainly C-reactive protein (CRP), have shown close asso-
ally suffer from various complications which are both ciation with cardiovascular morbidity and mortality [3].
uremic and dialysis associated [1, 2]. Particular impor-
tance in their development could be ascribed to the mi-
HEMODIALYSIS-ASSOCIATED OXIDATIVEcroinflammatory status [2], and to modification of biolog-
AND CARBONYL STRESSical structures both by oxidative and carbonyl stress apart
from other mechanisms (e.g., alteration of lipid metabo- Renal failure and dialysis treatment are both in line
lism, elevation of prothrombotic factors, and calcium/ with oxidative and carbonyl stress, which are closely
phosphate metabolisms disorders) [1, 2]. Both inflam- related. These pathogenic mechanisms modify biological
mation and oxidative/carbonyl stress damage seem to be structures (lipids, proteins, sugars, and nucleic acids) and
at least partly responsible for accelerated atherosclerosis cause their damage [1, 6]. Oxidative stress may be trig-
and, thus, increased cardiovascular morbidity and mor- gered due to interaction of blood with a bio-incompatible
tality (Fig. 1) [3]. dialysis membrane, increased through insufficient clear-
ance of reactive oxygen, nitrogen species, and carbonyl
compound, and as a consequence of decreased antioxi-HEMODIALYSIS AND MICROINFLAMMATION
dant defense (both enzymes and their cofactors and anti-HD patients are often susceptible to various inflam-
oxidant vitamins). Early oxidative and carbonyl stressmatory and infectious complications. Even patients in
markers (e.g., 8-isoprostane, malondialdehyde, and vari-
ous carbonyl compounds), as well as markers of ad-
Key words: advanced glycation end products, advanced oxidation pro-
vanced damage (AGEs, AOPP, ALEs) are increased intein products, oxidative and carbonyl stress, inflammation, acute-phase
reactants, autoantibodies, hemodialysis. the serum of HD patients [1, 7–9].
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Table 1. Relationship between AGEs and AOPP and inflammatory markers/acute-phase reactants, and some autoantibodies in chronic
renal insufficiency and HD patients
Inflammatory markers/acute phase reactants Autoantibodies
Cytokines and growth factors Other parameters (fibrinogen, Anticardiolipin antibodies
(TNF-, TNF--soluble orosomucoid, C3 and C4 com- (ACA-IgG and IgM),
receptor, IL-1R antagonist, ponent of complement, SAA, anti -2-glycoprotein 1
Correlations IL-6, M-CSF) CRP PAPP-A, -2-macroglobulin) antibodies
AGEs
Fluorescent NO IL-6 and TNF- [13] NO [13, 16]* NO* NO*
Pentosidin YES [8, 14, 15] NO* NO* NO*
CML YES [15] NO [13, 16] NO*
NO IL-6 and TNF- [13]
AOPP YES [8, 14] NO [8]* YES only fibrinogen, oroso- NO*
mucoid, and PAPP-A*
* Our findings. Abbreviations are: AGEs, advanced glycation end products; AOPP, advanced oxidation protein products; CML, carboxymethyllysine; M-CSF,
macrophage colony stimulating factor; CRP, C reactive protein; SAA, serum amyloid A; PAPP-A, pregnancy-associated plasma protein-A. Our findings  results
from our study in 34 HD patients. AOPP correlate with fibrinogen (r  0.53, P  0.05), orosomucoid (r  0.39, P  0.05), and PAPP-A (r  0.46, P  0.05).
to acute phase reactants [8, 13–16] (Table 1). Although
AGEs show several toxic effects and trigger CRP eleva-
tion in vitro [3], surprisingly, high AGE levels indicate
better survival, as shown by Schwedler [16] recently in
HD patients. Both AGE-modified proteins and CRP
were found in atherosclerotic plaques, as well.
Advanced oxidation protein products were demon-
strated as an independent risk factor for coronary artery
disease [17]. They show a closer relationship to inflam-
mation than AGEs as, in addition to cytokines [8, 14],
Fig. 1. Relationship between glycoxidation products and inflammation they also correlate with acute-phase reactants. We ob-
in hemodialysis patients. served a significant correlation of AOPP with prothrom-
botic fibrinogen (r  0.53, P  0.05), orosomucoid (r 
0.39, P  0.05), and PAPP-A (r  0.46, P  0.05), a
new outstanding marker of acute coronary syndrome [5]sure of new epitopes might trigger an autoimmune re-
(Table 1). Similar to AGEs, however, we did not findsponse, which results in the formation of autoantibodies.
any relationship of AOPP to specific autoantibodies–Elevation of anticardiolipin antibodies (ACA), for ex-
anticardiolipin antibodies and anti--2-glycoprotein 1ample, is characteristic for HD patients, as well (ACA
antibodies, although both could contribute to acceler-IgG 104.4  24.1 U/mL in patients vs. 5.7  2.9 U/mL
ated atherosclerosis.in controls, P  0.05; ACA IgM 106.2  34.0 U/mL in
In conclusion, oxidative stress shows a closer relation-patients vs. 4.6  3.3 U/mL in controls, P  0.05), and
ship to inflammation and acute-phase reaction than ad-their association to atherosclerosis and thrombosis is well
vanced glycation/glycoxidation, and its end products, ad-known [10].
vanced oxidation protein products could, thus, represent
a biochemical marker of special importance.
MICROINFLAMMATION AND
GLYCOXIDATION: ARE THEY RELATED? ACKNOWLEDGMENT
These pathogenic mechanisms are supposed to act syn-
Studies on AGEs in hemodialysis patients were supported by grant
ergically, nevertheless, their interaction is still under in- IGA MH CZ No NB/7035 – 3. The authors are thankful to Mr. Sˇpacˇele
vestigation. AGEs can modify proteins or may act via and Mr. Braun for technical assistance.
their specific receptors [11], which leads to production
Reprint requests to Marta Kalousova´, M.D., Institute of Medicalof pro-inflammarory cytokines, growth factors, and adhe-
Biochemistry, 1st Faculty of Medicine, Charles University, Katerˇinska´
sive molecules. Some AGEs, particularly carboxymeth- 32, CZ - 121 08 Prague 2, Czech Republic.
E-mail: mkalousova@hotmail.comyllysine, may also form in inflamed foci [12]. However,
in vivo studies give controversial results, as some investi-
REFERENCESgators describe a relationship of AGEs to some inflam-
matory markers in serum or plasma, while others do 1. Miyata T, Ypersele De Strihou C, Kurokawa K, Baynes JW:
Alterations in nonenzymatic biochemistry in uremia: Origin andnot—neither we have found any relationship of AGEs
Kalousova´ et al: Relationship between advanced glycoxidation end productsS-64
significance of “carbonyl stress” in long-term uremic complications. and their interaction with AGE-receptors in vascular disease and
diabetes mellitus. I. The AGE concept. Cardiovasc Res 37:586–600,Kidney Int 55:389–399, 1999
19982. Schwedler S, Schinzel R, Vaith P, Wanner C: Inflammation and
12. Anderson MM, Requena JR, Crowley JR, et al: The myeloperoxi-advanced glycation end products in uremia: Simple coexistence,
dase system of human phagocytes generates Nepsilon-(carboxy-potentiation or causal relationship? Kidney Int 59:S32–S36, 2001
methyl)lysine on proteins: A mechanism for producing advanced3. Zimmermann J, Herrlinger S, Pruy A, et al: Inflammation en-
glycation end products at sites of inflammation. J Clin Investhances cardiovascular risk and mortality in hemodialysis patients.
104:103–113, 1999Kidney Int 55:648–658, 1999
13. Sebekova K, Podracka L, Heidland A, Schinzel R: Enhanced4. El FARRA, Grudzinskas JG: Will PAPP-A be a biochemical
plasma levels of advanced glycation end products (AGE) and pro-marker for screening of Down’s syndrome in the first trimester?
inflammatory cytokines in children/adolescents with chronic renalEarly Pregnancy 1:4–12, 1995
insufficiency and after renal replacement therapy by dialysis and5. Bayes-Genis A, Conover CA, Overgaard MT, et al: Pregnancy-
transplantation – are they inter-related? Clin Nephrol 56:S21–S26,associated plasma protein A as a marker of acute coronary syn-
2001dromes. N Engl J Med 345:1022–1029, 2001
14. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, et al: Ad-6. Halliwell B: Drug antioxidant effects. A basis for drug selection?
vanced oxidation protein products as novel mediators of inflam-Drugs 42:237–242, 1991
mation and monocyte activation in chronic renal failure. J Immunol7. Spittle MA, Hoenich NA, Handelman GJ, et al: Oxidative stress 161:2524–2532, 1998
and inflammation in hemodialysis patients. Am J Kideny Dis 15. Uchimura T, Motomiya Y, Okamura H, et al: Marked increases
38:1408–1413, 2001 in macrophage colony-stimulating factor and interleukin-18 in
8. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al: maintenance hemodialysis patients: comparative study of advanced
Advanced oxidation protein products as a novel marker of oxida- glycation end products, carbomethyllysine and pentosidine. Neph-
tive stress in uremia. Kidney Int 49:1304–1313, 1996 ron 90: 2002, 401–407
9. Kalousova M, Zima T, Tesar V, Lachmanova J: Advanced glyca- 16. Schwedler BS, Metzger T, Schinzel R, Wanner C: Advanced
tion end products and advanced oxidation protein products in glycation end products and mortality in hemodialysis patients. Kid-
hemodialyzed patients. Blood Purif 20:531–536, 2002 ney Int 62: 2002, 301–310
10. George J, Afek A, Gilburd B, et al: Autoimmunity in atheroscle- 17. Kaneda H, Taguchi J, Ogasawara K, et al: Increased level of
rosis: Lessons from experimental models. Lupus 9:223–227, 2000 advanced oxidation protein products in patients with coronary
artery disease. Atherosclerosis 162: 2002, 221–22511. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP: AGEs
